Halozyme Therapeutics | HALO - Sales Revenues



Halozyme Therapeutics reported $206M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Acadia Pharmaceuticals USD 264.6M 20.28M Jun/2025
Agios Pharmaceuticals USD 12.45M 3.75M Jun/2025
Alnylam Pharmaceuticals USD 773.69M 179.5M Jun/2025
Amarin USD 72.74M 30.72M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
Baxter International USD 2.81B 180M Jun/2025
Cytokinetics USD 66.76M 65.16M Jun/2025
DBV Technologies USD 1.46M 712K Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Halozyme Therapeutics USD 206M 59M Jun/2025
Ionis Pharmaceuticals USD 452M 320M Jun/2025
MannKind USD 76.53M 1.82M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
United Therapeutics USD 798.6M 4.2M Jun/2025